Functional evidence for neurological and neurodegenerative discovery
Starting with ALS / motor-neuron disease functional phenotyping.
SWARMOSCOPE CNS is being developed with an initial focus on ALS and motor-neuron disease models. The platform is designed to help preclinical teams determine whether a treatment improves disease-relevant motor function at tolerated exposure, or merely changes general activity through sedation, stress, toxicity, or impaired physiology.
"Does the candidate improve disease-relevant motor function in the ALS model at tolerated exposure?"
Disease-relevant functional signals
Activity and locomotor pattern
Bout structure and movement initiation
Stimulus-response latency
Recovery after controlled challenge
Coordination and functional impairment signals
Dose-dependent trajectories
Survival and morphology context
Tracking confidence, protocol fidelity, and QC flags
A three-step ladder from technical to decision validity
Technical validity
Demonstrate robust tracking and event detection under realistic conditions including lighting variation, reflection, fish overlap, occlusion, and movement variation.
Biological validity
Show that the defined ALS zebrafish model and scientifically appropriate reference conditions produce reproducible expected functional patterns.
Decision validity
Test whether the combined functional response map improves candidate ranking, dose selection, or mammalian follow-up-study design compared with standard endpoints alone.
SWARMOSCOPE does not claim that a zebrafish ALS model predicts human clinical efficacy. The initial goal is to produce a reproducible, auditable, disease-model-specific functional evidence record.
From ALS to a cross-indication functional-safety layer
ALS / motor-neuron disease
Cross-indication functional-safety layer
Epilepsy / neural excitability
Parkinson's, Huntington's, and additional neurodegeneration programs
Across ALS, epilepsy, neurodegeneration, and other treatment programs, SWARMOSCOPE is designed to distinguish intended functional benefit from sedation, motor impairment, sensory disruption, stress, toxicity, and measurement artifacts.
Early cross-indication functional-safety evidence